Resultados de búsqueda - First Line

Comparison of 6 cycles with 4 cycles of chemotherapy and atezolizumab in the first-line treatment of ES-SCLC: a retrospective multicenter analysis. por Güzel, Halil Göksel, Salim, Derya Kıvrak, Kılıçkap, Saadettin, Kemal, Yasemin, Akosman, Cengiz, Köseoğlu, Çağlar, Coşkun, Alper, Orman, Seval, Efil, Safa Can, Baş, Onur

Ver este registro en EBSCOhost

Real-World Evidence of Atezolizumab Efficacy as Part of First-Line Treatment for Extensive-Stage SCLC in Bulgaria. por Manova, Manoela, Ivanova, Boryana, Krasteva, Rositsa, Conev, Nikolay, Zlatanova, Tanya, Arabadjiev, Jeliazko, Chilingirova, Natalia, Petrova, Mila, Dudov, Assen, Robev, Bozhil, Minchev, Velko, Tonev, Ivan, Koynov, Krassimir, Penchev, Daniel, Georgiev, Todor, Rangelov, Antoan, Savova, Alexandra

Ver este registro en EBSCOhost

Analysis of the Correlation between Immune Cell Subsets in Bronchoalveolar Lavage Fluid and the Efficacy of First-line Use of Immunotherapy in Advanced Non-small Cell Lung Cancer:... por Kai ZHANG, Liang SHI, Tongmei ZHANG, Li TONG, Song WEI, Hongxia LI

Ver este registro en EBSCOhost

Pharmacokinetics-pharmacodynamics of first-line antitubercular drugs: a comparative study in tuberculosis patients with and without concomitant diabetes mellitus. por Mondal, Sourav, Roy, Vandana, Meshram, Girish Gulab, Khanna, Ashwani, Velpandian, Thirumurthy, Garg, Sandeep

Ver este registro en EBSCOhost

Real-World Primary Resistance to First-Line Immune-Based Combinations in Patients with Advanced Renal Cell Carcinoma (ARON-1). por Santini, Daniele, Li, Haoran, Roviello, Giandomenico, Park, Se Hoon, Grande, Enrique, Kucharz, Jakub, Basso, Umberto, Fiala, Ondrej, Monteiro, Fernando Sabino Marques, Poprach, Alexandr, Buti, Sebastiano, Molina-Cerrillo, Javier, Catalano, Martina, Buchler, Tomas, Seront, Emmanuel, Ansari, Jawaher, Myint, Zin W., Ghosn, Marwan, Calabrò, Fabio, Kopp, Ray Manneh

Ver este registro en EBSCOhost

Is atezolizumab plus bevacizumab as first-line therapy for unresectable hepatocellular carcinoma superior to lenvatinib? a systematic review and meta‑analysis. por Zhu, Gang, Zeng, Longfei, Yang, Liu, Zhang, Xin, Tang, Jinquan, Pan, Yong, Li, Bo, Chen, Mengchen, Wu, Tao

Ver este registro en EBSCOhost

THE MUCOSAL IMMUNE SYSTEM: THE DELICATE BALANCE BEHIND YOUR BODY'S FIRST LINE OF DEFENCE. por GINTA, DANIELA

Ver este registro en EBSCOhost

Complete Blood Count-Based Biomarkers as Predictors of Clinical Outcomes in Advanced Non-Small Cell Lung Cancer Patients with PD-L1 < 50% Treated with First-Line Chemoimmunotherapy... por Putzu, Carlo, Serra, Riccardo, Campus, Rachele, Fadda, Giovanni Maria, Sini, Claudio, Marongiu, Andrea, Ginesu, Giorgio Carlo, Fois, Alessandro Giuseppe, Palmieri, Giuseppe, Zinellu, Angelo, Cossu, Antonio, Paliogiannis, Panagiotis

Ver este registro en EBSCOhost

First‐line or second‐line PD‐1 inhibition in advanced oesophageal squamous cell carcinoma: A prospective, multicentre, registry study. por Li, Xu‐Yuan, Huang, Li‐Sheng, Cai, Hao‐Quan, Huang, Wan‐Lan, Huang, Xiao‐Long

Ver este registro en EBSCOhost

Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+/HER2− advanced breast cancer receiving first-line ribociclib plus fulvestrant. por Neven, P., Fasching, P. A., Chia, S., Jerusalem, G., De Laurentiis, M., Im, S.-A., Petrakova, K., Bianchi, G. V., Martín, M., Nusch, A., Sonke, G. S., De la Cruz-Merino, L., Beck, J. T., Zarate, J. P., Wang, Y., Chakravartty, A., Wang, C., Slamon, D. J.

Ver este registro en EBSCOhost

Long-term outcomes and treatment cessation in patients with long term response to first line treatment of metastatic prostate cancer. por Meeks, Monica, Iranmanesh, Yasaman, Song, Hyunsoo, Blackford, Amanda L, Rasouli, Arya, Baras, Alex, Denmeade, Samuel R, Markowski, Mark C, Paller, Channing J, Carducci, Michael A, Antonarakis, Emmanuel S, Eisenberger, Mario A, Marshall, Catherine H

Ver este registro en EBSCOhost

International practice patterns in the use of ultrasound as first-line imaging for suspected midgut volvulus in children: a joint society for pediatric radiology–European society o... por Tutman, Jeffrey, Perucca, Giulia, Chan, Sherwin, El-Ali, Alexander, Kljucevsek, Damjana, Limantoro, Ione, Riccabona, Michael, Petit, Philippe, Nguyen, HaiThuy N., Samet, Jonathan

Ver este registro en EBSCOhost

Summary of Research: HER2CLIMB-05: A Phase III Study of Tucatinib Versus Placebo in Combination with Trastuzumab and Pertuzumab as First-Line Maintenance Therapy for HER2+ Metastat... por Dieras, Veronique, Curigliano, Giuseppe, Martin, Miguel, Lerebours, Florence, Tsurutani, Junji, Savard, Marie-France, Jerzak, Katarzyna J., Hu, Xichun, O’Sullivan, Ciara C., Tokunaga, Eriko, Okines, Alicia, Huang, Chiun-Sheng, Jacot, William, Sohn, Joohyuk, Cronemberger Silva, Eduardo, Mueller, Volkmar, Yang, Shan, Granata, Giovanna, Shen, Qi, Hamilton, Erika

Ver este registro en EBSCOhost

First-line biologic and targeted synthetic DMARDs versus methotrexate in early rheumatoid arthritis: a meta-analysis of remission outcomes. por Russell, Mark D, Chan, Chun J, Sasitharan, Aran, Allen, Victoria, Gibson, Mark, Adas, Maryam A, Goodliffe, Samantha, Bechman, Katie, Cope, Andrew P, Norton, Sam, Bosworth, Ailsa, Foxton, Peter, Price, Elizabeth, Sharrack, Sana, Dass, Shouvik, Emery, Paul, Kay, Lesley, Lanyon, Peter, Galloway, James B

Ver este registro en EBSCOhost

Evaluation of QTc interval prolongation in patients with advanced clear cell renal cell carcinoma treated with first line sunitinib. por Sałek-Zań, Agata, Püsküllüoğlu, Mirosława, Stąpór, Agnieszka, Jaworska, Justyna, Pietruszka, Agnieszka, Grela-Wojewoda, Aleksandra, Stąpór, Maciej, Banaś, Tomasz

Ver este registro en EBSCOhost

One-Week Inflammatory Kinetics After First-Line Nivolumab Plus Ipilimumab in Metastatic Renal Cell Carcinoma: A Multicenter Landmark Analysis. por Inoue, Toru, Numakura, Kazuyuki, Osawa, Takahiro, Naito, Sei, Ishihara, Takuma, Ohba, Kojiro, Ueda, Kosuke, Sekine, Yuya, Oki, Masaharu, Naito, Hirohito, Miyata, Haruka, Kikuchi, Hiroshi, Kobayashi, Shin, Narita, Shintaro, Tsuchiya, Norihiko, Sugimoto, Mikio, Igawa, Tsukasa, Shin, Toshitaka

Ver este registro en EBSCOhost

Effectiveness and Safety of Risankizumab in Crohn Disease After Failure of a First Line of Advanced Therapy: A Long-Term, Real-Life Study. por Tursi, Antonio, Mocci, Giammarco, Scaldaferri, Franco, Napolitano, Daniele, Gaiani, Federica, De' Angelis, Gianluigi, Ribaldone, Davide Giuseppe, Schillaci, Eleonora, Savarino, Edoardo V., Barba, Caterina D. E., Bendia, Emanuele, Bolognini, Laura, Balducci, Daniele, Quatraccioni, Claudia, Martini, Francesco, Montori, Michele, Giovanni Maconi, Cataletti, Giovanni, Massari, Alessandro, Del Zanna, Elena

Ver este registro en EBSCOhost

Efficacy and safety of first-line immune checkpoint inhibitor–based combination therapy in metastatic renal cell carcinoma patients on hemodialysis. por Takahashi, Hidetsugu, Fukuokaya, Wataru, Yanagisawa, Takafumi, Okamoto, Maria, Urabe, Fumihiko, Mori, Keiichiro, Nishimura, Shingo, Maenosono, Ryoichi, Toyoda, Shingo, Nukaya, Takuhisa, Morinaka, Hirofumi, Tamura, Keita, Araki, Motoo, Azuma, Haruhito, Fujita, Kazutoshi, Takahara, Kiyoshi, Komura, Kazumasa, Inamoto, Teruo, Kimura, Takahiro

Ver este registro en EBSCOhost

First-Line Pembrolizumab Plus Chemotherapy for Advanced Biliary Tract Cancer: China Subgroup Analysis of the Randomized Phase 3 KEYNOTE-966 Study. por Ren, Zhenggang, Liang, Tingbo, Gu, Shanzhi, Gou, Hongfeng, Peng, Chuang, Pan, Yueyin, Song, Tianqiang, Su, Haichuan, Cao, Ke, Liang, Houjie, Ying, Jieer, Geng, Zhimin, Yu, Wenchang, Zhao, Haitao, Bai, Yuxian, Hao, Chunyi, Mao, Yimin, Li, Wei, Wang, Lu, Li, Dongliang

Ver este registro en EBSCOhost

Efficacy and safety of immunotherapy-based combination therapy as first-line treatment for advanced renal cell carcinoma: a systematic review and network meta-analysis. por Ou, Xiaoyu, Li, Yan, Zhan, Mengru, Tao, Tiantian, Chen, Pingyu

Ver este registro en EBSCOhost